A paper about GHK should not silently become evidence about GHK-Cu. This report identifies the tripeptide GHK as its intervention. Primary report
What was studied
Mice received bleomycin to induce lung injury and fibrosis. GHK treatment began after induction, and tissue was assessed at three weeks. The authors reported reduced fibrotic and inflammatory measurements, with changes in TGF-beta/Smad-associated and epithelial-to-mesenchymal-transition markers. This was an induced animal model, not a trial in idiopathic pulmonary fibrosis. Primary report
Our appraisal: markers and cell fate are different levels of proof
A tissue marker pattern can be consistent with a proposed transition without demonstrating the complete history of individual cells. Strong claims about cell origin and fate need methods designed to track those processes. The marker findings remain useful, but their evidentiary level should be explicit.
The injury schedule also constrains interpretation. Beginning treatment after an inducing insult is not automatically equivalent to treating longstanding progressive disease. The stage of inflammation and fibrosis at treatment initiation matters as much as the calendar day.
Compound identity is another boundary. A shared peptide sequence does not justify assuming identical exposure or biological activity across copper-complexed, uncomplexed, or formulated preparations. Evidence should be assigned to the preparation actually tested.
Full review should examine histological scoring, blinded assessment, biochemical measures, and whether functional lung outcomes support the tissue interpretation. It should also avoid repeating the article's historical background as current treatment guidance. This is a preclinical fibrosis record, not a present-day statement about all available clinical therapies or a recommendation to use research GHK.
Frequently asked questions
What intervention does the paper identify?
GHK.
Should it be relabeled GHK-Cu?
No.
What induced the mouse lung injury?
Bleomycin.
Was human idiopathic pulmonary fibrosis treated?
No.
Do tissue markers alone establish individual cell fate?
No.
Does post-injury treatment necessarily mean late-stage disease treatment?
No.
What should a summary preserve?
Preparation identity, model stage, measured endpoints, and mechanistic uncertainty.